DYN

🏥 Healthcare

Dyne Therapeutics, Inc.

Conservative #1023Aggressive #418Moderate RiskMixed 59F↑ 21pt

$16.09+3.54%

Day High$16.16

Day Low$15.22

Volume2.3M

Mkt Cap$2.6B

52W Low $652W High $25

Market Cap

$2.4B

P/E Ratio

N/A

Rev Growth

0.0%

Sector avg: 161.5%

Earnings Growth

-34.5%

Profit Margin

0.0%

Sector avg: -3292.7%

Debt/Equity

0.17

Why This Score

DYN scores 33.3 on the Conservative profile, blending a fundamental score (80% weight, emphasizing quality and stability (84% of fundamental weight)) with a machine-learning signal (20% weight) trained on 82 features across 30 years of data.

Strengths

Positive but moderate momentum (14%) — steady appreciation without overheating.
ML model assigns a high-conviction signal (98/100), indicating strong pattern recognition across 82 features.

Risk Factors

Signal divergence: Fundamental and ML signals disagree by a significant margin, reducing confidence.
Above-average volatility (27.2%) may not suit conservative risk tolerance.

Moderate penalties (-8.5 points) reflect identified risk factors. The overall score balances these against the stock's fundamental strengths.

Score Breakdown

Overall Score33.3

Fundamental Score27.4

ML Score98.0

Score by Horizon

3 Month

18.7

6 Month

20.9

Primary

1 Year

22.0

Quality Assessment

Earnings Grade

Strong fundamentals, high earnings quality

Quality Flags

Pipeline concentration: $2.4B biotech/pharma — likely single-product revenue with binary risk

Position Sizing

Suggested Allocation

2.9%

Confidence

high

Score Composition Waterfall

How each component affects the final score

Backtested Scoring Levers (IC-calibrated from 30y ElasticNet)

Weinstein (12.1%)

100

Advancing

Sentiment (2.5%)

Positive

Analyst (6.4%)

Favorable

Tradability (post-hoc)

Grade A

Base

41.5

SHAP

+0.2

Factors

-0.1

Divergence

-8.3

Final

33.3

Positive adjustment

Negative adjustment

Base blend

Final score

Signal SegmentsComputed from ML features

Fundamental (Valuation, Quality, Growth)41.0

Technical (Momentum, Weinstein, Volatility)63.0

External (Sentiment, Analyst, Macro)88.0

Scores below 50 indicate weakness in that segment relative to the universe.

Data Quality

Score

Features

Confidence

Feature Coverage89%

Growth Estimates

Short-term

-6.5% to -1.5%

Medium-term

-9.0% to -1.6%

Long-term

-11.5% to -1.8%

ML Model Core Features100 trained inputs → ML Score: 98

These features are direct inputs to the machine learning model. The model was trained on these signals alongside 100 features (including 12 momentum/technical indicators) to produce the ML percentile score.

Analyst Intelligence

Consensus Score75.0/100

Target Upside+152.5%

Coverage13 analysts

Market Sentiment

Sentiment Score76.6/100

News Volume1 articles

Technical Stage

Weinstein Stage2 — Advancing

12M Momentum+0.1%

6M Momentum+0.2%

Volatility+0.3%

Momentum & Technical

Momentum Acceleration-1.0%

Momentum ConsistencyStrong (0.93)

Relative Strength vs Sector-10.2%

Trend Strength (ADX Proxy)Weak (0.5)

Momentum Quality+0.098

Momentum BreadthBroad ✓

Macro Regime

Bull RegimeYes

High Vol RegimeNo

S&P 500 Return+25.0%

Yield Curve-0.1bp

Sector-Relative AnalysisIn-model features

Value Trap Signal

Low risk

Sector RevGr Rank

P41

Revenue growth vs Healthcare peers

Sector PE Rank

P40

Valuation vs Healthcare peers

Sector FCF Rank

P12

Free cash flow vs Healthcare peers

Growth Deviation

-0.0σ

Z-score vs sector median

Stagnation Flag

Not flagged

Analysis Signals

Scoring Factors

Fundamental score of 55 relative to sector peers55/100

Machine learning model ranks this stock at the 34th percentileP34

ML model weight reduced to 9% due to macro conditions: market in extended rally phase; yield curve inverted (recession indicator); late-cycle economic indicators detected9% ML weight

SHAP feature alignment: +0.2pt (features align with model priorities)—

Blend: 91% fund (54.9) + 9% ML (32.4) + SHAP(+0.2) = 53.0—

Factor quality: -0.1pt (multi-factor composite)—

Risk assessment: moderate. Annualized volatility 27.2%. Max drawdown 31% (-9.3 pts)Moderate

Market cap adjustment: -4.0 points ($2.4B market cap)-4.0 pts

Divergence penalty: -1.5pt (fund 21pt higher)—

Risk Factors

Earnings quality grade A: strong earnings quality and financial health. Score adjusted by -7 pointsGrade A

Quality concern: Pipeline concentration: $2.4B biotech/pharma — likely single-product revenue with binary riskFlag

Sector Peer Comparison(Healthcare — Rank #182 of 344 stocks)

Stock	Score	P/E	Rev Growth	Margin	Mkt Cap
DYNDyne Therapeutics, Inc.	33.3	N/A	0.0%	0.0%	$2.4B
INCYIncyte Corporation	89.6	15.8	21.2%	25.0%	$20.1B
GMABGenmab A/S	85.5	13.1	22.8%	36.4%	$18.5B
CPRXCatalyst Pharmaceuticals, Inc.	82.2	13.7	23.5%	37.6%	$3.0B
VRTXVertex Pharmaceuticals Incorpor	78.0	32.1	8.9%	32.9%	$126.0B
ASNDAscendis Pharma A/S	75.7	16.6	98.0%	-31.7%	$13.3B
NBIXNeurocrine Biosciences, Inc.	74.7	26.5	21.4%	16.7%	$12.5B
ALKSAlkermes plc	74.6	16.5	-6.4%	23.9%	$5.5B
AMGNAmgen Inc.	73.8	26.0	10.0%	21.0%	$199.0B
ARGXargenx SE	73.6	35.1	78.6%	38.0%	$50.9B
HOLXHologic, Inc.	73.3	31.1	1.7%	13.8%	$16.8B
REGNRegeneron Pharmaceuticals, Inc.	72.7	19.4	1.0%	31.4%	$84.9B
ISRGIntuitive Surgical, Inc.	72.3	61.7	20.5%	28.4%	$172.5B
EXELExelixis, Inc.	71.9	15.1	7.0%	33.7%	$11.7B
KRYSKrystal Biotech, Inc.	71.0	41.4	473.0%	30.7%	$8.0B
HALOHalozyme Therapeutics, Inc.	70.2	16.8	22.4%	43.7%	$9.3B
Sector Average	37.1	252.3	161.5%	-3292.7%	—

Market Sentimentvia FMP

Analyst Consensus

Buy13 analysts

Strong Buy: 1Buy: 11Hold: 1

Price Target

$38consensus

Low $23Median $39High $60

+135.5% to consensus target

Company Overviewvia FMP

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..

CEO

John G. Cox

Employees

192

Beta

1.31

Industry

Biotechnology

FMP-Identified Peers

AAPG APGE CELC CGON CNTA MIRM RARE SLNO TLX XENE

Technical Picturecomputed from daily prices

RSI (14)

32.0

Neutral

Trend

Bearish

10-day vs 50-day MA

From 52W High

-35.6%

High: $25

From 52W Low

+153%

Low: $6.36

Moving Averages

10-Day

$15.60

Above

20-Day

$16.60

Below

50-Day

$17.80

Below

200-Day

$15.00

Above

60-Day Support

$14.56

60-Day Resistance

$23.96

Weinstein Stage Analysisbased on 200-day SMA framework

Stage 2 — AdvancingScore: 75/100

Stock is in an uptrend above the 200-day moving average. This is the stage where institutional accumulation typically occurs. The 50-day SMA provides support.

Favorable technical position; 50-day SMA acts as support

Price vs 200 SMA

+7.3%

200 SMA Slope (60d)

+16.25%

Rising

Volume Ratio

0.87x

10d avg vs 50d avg

Days in Stage

Confidence: 90%

Financial Statementslast 4 quarters via FMP

Metric	Q3 2025	Q2 2025	Q1 2025	Q4 2024
Revenue	$0	$0	$0	$0
Gross Profit	$0	$0	$0	$0
Operating Income	$-114M	$-116M	$-122M	$-97M
Net Income	$-108M	$-111M	$-115M	$-90M
EPS (Diluted)	$-0.76	$-0.97	$-1.05	$-0.88
Gross Margin	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A

Why This Stock

Healthcare

Tradability FilterGrade A — 92/100Score impact: -40.9pt

Volume

100

2.5M avg/day

Dollar Vol

$38M/day

Float

100

134M shares

Mkt Cap

$2.4B

Range

100

293% spread

Composite Liquidity Score92/100

FDCBA

Multi-Year Range Analysis

Sideways: 0/100

Year	Low	High	Range	Status
2021	$11.57	$22.92	65.9%	Wide
2022	$4.30	$15.63	113.7%	Wide
2023	$6.40	$15.60	83.6%	Wide
2024	$12.33	$47.45	117.5%	Wide
2025	$6.36	$26.22	121.9%	Wide

3-Year Range

152.7%

Narrow Years

0 / 5

Sideways Penalty

None

Free Float

82.9%

Outstanding Shares

162M

Bid-Ask Spread

293.0%

Institutional Tradable

Yes

Scores are generated by a multi-stage ML pipeline combining fundamental analysis, ensemble predictions, and structural risk signals. All data is for research purposes only and does not constitute financial advice. Past performance does not guarantee future results.